Summit Therapeutics Inc. (SMMT) Dividend History

Company News

• 3 Monster Stocks in the Making to Buy Right Now

  Three biotech companies - CRISPR Therapeutics, Summit Therapeutics, and Viking Therapeutics - show significant potential for growth in gene editing, cancer treatment, and obesity/metabolic disease markets.

  The Motley Fool

  Featured Companies: CRSP VKTX VRTX
• Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug

  Merck agreed to acquire Verona Pharma for $10 billion, gaining Ohtuvayre, a novel COPD maintenance therapy drug recently approved by the FDA, to strengthen its respiratory disease portfolio.

  Benzinga

  Featured Companies: MRK
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NWTN Inc. - NWTN

  Pomerantz LLP is investigating claims on behalf of investors of NWTN Inc. and Summit Therapeutics Inc. due to potential securities fraud or other unlawful business practices. NWTN's stock price fell 32% after the company received a delisting notice from Nasdaq.

  GlobeNewswire Inc.

  Featured Companies: NWTN
• MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?

  Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.

  Zacks Investment Research

  Featured Companies: MRK MRNA
• Wall Street Breakfast: The Week Ahead

  Stay updated with the latest financial news and market trends by listening to the Wall Street Breakfast podcast available on Seeking Alpha, iTunes, and...

  Seeking Alpha

  Featured Companies: ABBV ACI BA BOLD BYND CART CAT CL CMCSA CMG CPNG CPRI CVX F GD GM GOOG GOOGL HLT IBM INTC LMT MAT META MMA MO MRK MSFT NVDA PEP PERI PM RILY SNAP SUN T TFC TPR TSLA TXN UBXG UPS URBN V VZ XOM